Samsung Biologics Surpasses $1.44 Billion Sales in First Half
Company Plans to Begin Operations of Dedicated ADC Production Facility by Year-End
Samsung Biologics, a CDMO (Contract Development and Manufacturing Organization) company, has surpassed $1.44 billion in sales for the first half of the year. The company is now aiming to start operations of its dedicated Antibody-Drug Conjugate (ADC) production facility by the end of the year.
According to industry sources on July 26th, Samsung Biologics plans to initiate GMP (Good Manufacturing Practice) readiness for its ADC-dedicated plant by December. A company representative stated, "We are constructing an ADC production plant with the goal of achieving GMP readiness by December this year, but we cannot disclose specific operational plans at this time."
Samsung Biologics is actively investing in the ADC sector as part of its portfolio expansion strategy. The company is building the ADC-dedicated plant with the aim of starting operations within the year. Once operational, it is expected to secure CMO (Contract Manufacturing Organization) contracts with global pharmaceutical giants. The company is currently in ongoing discussions with various clients for product orders.
To secure its competitiveness in the ADC field and proactively respond to the market, Samsung Biologics has invested in companies with ADC technology, such as Araris Biotech AG and Aimed Bio. In April 2023, Samsung Biologics and Samsung C&T invested in the Swiss company Araris Biotech, which holds exclusive ADC linker technology, through the Samsung Life Science Fund.
The Life Science Fund, formed by Samsung C&T, Samsung Biologics, and Samsung Bioepis, also invested in the South Korean biotech company Aimed Bio last September. At that time, Samsung Biologics announced joint research with Aimed Bio on the development of an ADC toolbox, in addition to equity investment.
A representative from Samsung Biologics stated, "We will continue to secure ADC-related technology for future growth and will consider strategic investments (SI) based on the potential for synergy with our business."
Industry experts believe that Samsung Biologics' ADC CDMO business will become a new growth engine for the company. Yoon-taek Jung, Director of the Pharmaceutical Industry Strategy Research Institute, commented, "ADC is a promising modality, and it is anticipated that ADC drugs will continue to receive approval from the US FDA. The ADC CDMO business can contribute to the new growth of Samsung Biologics."